On September 7th, CSO speaks about monogenic disease modeling using NuHeart™ technology during TERM for heart, blood vessel & lung session.
99-O-5: Personalized micro-3D human heart
tissues for orphan drug development
Tetsuro Wakatsuki，Neil Daily，Pinar Kemanli，
Michael Greenberg，Jennifer Strande
InvivoSciences, Inc. Madison Wisconsin, USA, Washington University, St. Louis, Medical College of Wisconsin.
InvivoSciences, Inc. is collaborating with Drs. Elson and Qian to establish a novel mathematical model to understand the development of cardiac fibrosis during heart failure. The model will be used to identify and validate new therapeutic targets to prevent, slow, or reverse cardiac fibrosis.
Goldman Sachs 10,000 small business SUMMIT
Industry leaders, experts, and policymakers will speak with CEO during the two-day interactive program.